Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Says Yes To Akcea’s Tegsedi After ‘Improved’ Commercial Offer

Executive Summary

NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”

You may also be interested in...



NICE Rejects Akcea’s High-Cost Waylivra

Initial knock-back from NICE means Akcea will need to improve commercial offer.

Akcea C-Suite Upheaval’s Reasons Unclear, Firm Set To Take In More Ionis Programs

Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.

A Win For Alnylam In England As NICE Reverses Onpattro Rejection

Health technology appraisal body NICE now says that Alnylam's innovative gene silencing drug is value for money for the treatment of the rare disease, hereditary transthyretin-related amyloidosis.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS125135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel